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Abstract: At the moment, several COVID-19 scoring systems have been developed. It is necessary to
determine which one better predicts a poor outcome of the disease. We conducted a single-center
prospective cohort study to validate four COVID-19 prognosis scores in adult patients with confirmed
infection at ward. These are National Early Warning Score (NEWS) 2, Lung Ultrasound Score
(LUS), COVID-19 Worsening Score (COWS), and Spanish Society of Infectious Diseases and Clinical
Microbiology score (SEIMC Score). Our outcomes were the combined variable “poor outcome” (non-
invasive mechanical ventilation, intubation, intensive care unit admission, and death at 28 days) and
death at 28 days. Scores were analysed using univariate logistic regression models, receiver operating
characteristic curves, and areas under the curve. Eighty-one patients were included, from which
21 had a poor outcome, and 9 died. We found a statistically significant correlation between poor
outcome and NEWS2, LUS > 15, and COWS. Death at 28 days was statistically correlated with NEWS2
and SEIMC Score although COWS also performs well. NEWS2, LUS, and COWS accurately predict
poor outcome; and NEWS2, SEIMC Score, and COWS are useful for anticipating death at 28 days.
Lung ultrasound is a diagnostic tool that should be included in COVID-19 patients evaluation.
Keywords: SARS-CoV-2; COVID-19; lung; ultrasound; early warning score
1. Introduction
Pneumonia caused by SARS-CoV-2 (COVID-19) has been an unprecedented health
disruption in recent decades. In December 2019, a lung disease outbreak due to a previously
unknown pathogen was announced in the city of Wuhan, China. Since then, according to
the Coronavirus Resource Center at Johns Hopkins University, as of 1 June 2021, more than
170 million cases and 3.5 million deaths have been reported all around the world [1]. Of
these data, more than 50 million cases correspond to Europe and, in particular, more than
3.5 million to Spain [2]. This has resulted in 250,000 hospital admissions in Spain, from
which 25,000 went to intensive care units [3].
One of the difficulties in assessment and management lies on knowing which patients
will have a more unfavourable evolution. Acute respiratory distress syndrome (ARDS) is
the worse consequence of SARS-CoV-2 inflammatory process in the lungs, needing frequent
high-flow nasal oxygen therapy or noninvasive mechanical ventilation (NIMV), invasive
mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO) in critical
cases [4]. This leads to an overuse of intensive care unit resources, extended hospital stays,
and a high mortality rate of this population.
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Several scoring systems have tried to classify patients at admission [5–9]. Classifying
patients has the utility of trying to predict which of them may have a worse outcome in
order to provide them an earlier administration of ventilatory support or drugs that change
the patient’s prognosis. These scores are usually based on clinical and/or analytical data.
However, lung ultrasound has been reported to be a promising tool for the diagno-
sis and follow-up of pneumonia, interstitial diseases, and ARDS [10,11]. Lung damage
originated from COVID-19 is typically patchy and subpleural, which makes COVID-19
specially interesting to be evaluated by lung ultrasound [12]. Its role in the pandemic has
so far been secondary, but it has proven to be a useful tool for the stratification of severity
and risk of death in these patients [13], as supported by a strong correlation between lung
ultrasound and CT, with greater accessibility and speed at lower cost [14].
The aim of our study is to evaluate some of these scoring systems in order to validate
them and assess which one of them better predicts a worse outcome in our cohort.
2. Materials and Methods
2.1. Study Design and Setting
We conducted a single-center prospective cohort study to validate four COVID-19
prognosis scores. The study protocol was approved by the regional ethics committee with
the code 0259-N-21. This study was written in accordance with the TRIPOD statement for
risk prediction models [15]. It was conducted at the San Cecilio University Hospital in
Granada (Spain), with a reference population of almost 500,000 people.
2.2. Selection of Participants
This study included consecutive adult patients (age 18 years or older) by quota
sampling, with infection confirmed by real-time reverse transcription–polymerase chain
reaction (RT–PCR) to be SARS-CoV-2 positive [16], in the first 24 h of admission to the
COVID-19 inpatient ward from 1 January 2021 to 20 March 2021.
Patients with suspected or confirmed bacterial pulmonary superinfection, those unable
to cooperate with the examination (for physical or cognitive reasons), and those who
voluntarily refused to participate were excluded from the study. All patients were given a
study summary and signed an informed consent form with the possibility of revocation.
2.3. Measurements
Registration data, anthropometric variables, symptoms and onset date, comorbidities,
vital signs, radiological severity, analytical data, and ultrasound lung involvement were
compiled. The researchers on the COVID-19 transitional hospitalisation ward collected
those clinical variables at the time of evaluation. The Emergency Department requested
the analytical data at the first hospital contact, whereas the missing data were completed
during the examination.
Ultrasound imaging was performed with an ultrasound scanner PHILIPS® SPARQ
(Koninklijke Philips N. V.; Amsterdam, The Netherlands). The predefined lung programme
was established, using a convex transducer 6–2 MHz. The Clinical Care Ultrasound Group
of the hospital trained 6 Internal Medicine physicians in lung ultrasound, who obtained
the images. At least 2 examiners were present when the ultrasound images were acquired
in order to reduce the inherent inter-individual variability in this technique. We used
a 12 lung fields protocol, as it is the protocol that has shown the best balance between
accuracy and acquisition time [17]. The clavicular midline and paravertebral line divided
each hemithorax into anterior, lateral, and posterior fields. These fields were further
subdivided into superior and posterior fields, resulting in 6 fields in each lung (Figure 1).
Prior examination of the patients medical history was avoided to prevent possible biases in
image acquisition.
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Figure 1. Lung areas distribution and LUS score as described by Soldati et al. [7]: (a) 0 points
(normal A-lines pattern); (b) 1 point (>3 B-lines); (c) 2 points (subpleural consolidation); (d) 3 points
(pulmonary consolidation or “with lung”).
2.4. Outcomes
Outcomes collected were non-invasive mechanical ventilation or high-flow nasal
oxygen therapy (NIMV), intubation (IMV), intensive care unit (ICU) admission, and death
at 28 days. The combined outcome variables NIMV or IMV and NIMV or IMV or ICU
admission or death at 28 days were also elaborated. Our primary variable was the combined
variable poor outcome (NIMV or IMV or ICU admission or death at 28 days) and the
secondary variable death at 28 days.
2.5. Scores Selection
The studied scores cover clinical, analytical, and imaging variables associated with
poor prognosis in the e olution of COVID-19.
National Early Warning Score (NEWS) 2 [5], recognised in previous studies as a useful
prognostic tool and superi r to other scales in COVID 19 fo both severe illness and in-
h spital mortality [18], was used to an lyse the prognostic value of clin cal data. This
takes into account vital sign , such as heart rate, syst lic blood pressure, respiratory rate,
peripheral oxygen saturation (S O2), and bod temperature; and it also includes the need
for oxygen supply and the level of consciousness.
Furthermore, t most widely recogni ed international index for lung ultrasound in
COVID-19 is the Lung Ultrasound Score (LUS) [11]. It scores from 0 to 3 each of the fields
analysed, depending on the severity of the findings in each of them, as shown in Figure 1.
The final sum of the score for all fields is used as a prognostic value. It was developed only
correlating the score with clinical severity [7].
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In addition to the scores mentioned above, two other indexes that include two or more
of these categories were analysed. The COVID-19 Worsening Score (COWS) measures
both LUS >15 points and clinical and analytical variables of the previously validated
COVID-GRAM score [19], including dyspnea, symptom days, arterial oxygen pressure
to oxygen inspired fraction ratio, and number of co-morbidities, including dementia,
chronic obstructive pulmonary disease (COPD), chronic renal disease (CRD), diabetes
mellitus (DM), hypertension, obesity, neoplasm, hepatitis B virus, cerebrovascular disease,
cardiovascular disease, heart failure, and immunosuppression. The COWS measures the
likelihood of developing severe disease in hospitalised patients [8]. Another prognostic
tool is the COVID-19 Spanish Society of Infectious Diseases and Clinical Microbiology
score (SEIMC Score), which studies clinical and analytical variables, such as age, low
age-adjusted SaO2, neutrophil to lymphocyte ratio, estimated glomerular filtration rate,
dyspnea, and sex in hospitalised patients and correlates it with 30-day mortality [9].
2.6. Analysis
Based on the data available at the beginning of the study, an estimated sample cal-
culation of 22 patients was made to perform mean differences. We performed a simple
logistic regression assuming an alpha of 0.05, a beta of 0.8, a probability of the event in the
null hypothesis of 0.3, and a probability of the event in the alternative hypothesis of 0.7,
with an estimated proportion of the population with the alternative hypothesis of 0.3. We
set >15 as the severity cutoff point in the LUS, as used by COWS [8].
Descriptive statistics on the patients subjected to the ultrasonography exploration
were performed by means and ranges for discrete variables, median, and inter-quartile
ranges for continuous variables. For this analysis, normality was verified using the Shapiro–
Wilk test. Non-normal variables means differences were tested using the Mann–Whitney
test and the chi-square test for categorical variables. The main statistical analyses were
derived in order to explore the relationship between our principal and second outcomes
with several indices detailed above, such as NEWS2, LUS, COWS, or SEIMC Score. The
methods consisted of univariate logistic regression models, estimating the risk of low index
versus high index per unit depending on the classification. Receiver operating characteristic
(ROC) curves were calculated to evaluate the predictive performance of these five scores for
our primary and secondary outcomes. Areas under the curve (AUC) and 95% confidence
intervals (CI) were also calculated. The cut-off point for the AUC was set at 0.7. This value
indicates a favourable result, especially for the validation of a new score [20].
All tests were two-sided, and we determined a p-value < 0.05 and an AUC > 0.7 as
significant. Data derivation procedure was calculated using SSPS software, version 24 (IBM
Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY, USA:
IBM Corp.).
3. Results
3.1. Characteristics of Study Subjects
Between 1 January and 20 March, a total of 769 patients were admitted to the COVID-
19 hospitalisation ward of the San Cecilio University Hospital with a positive SARS-CoV-2
PCR, and 656 of those were admitted diagnosed of COVID-19 pneumonia. Of the remaining,
198 had one or more of the exclusion criteria described above. Finally, of the 458 eligible
patients, 81 successive patients could be included in the study depending on the availability
of human and material resources, as described in Figure 2.
The baseline characteristics of the participants are listed in Appendix A. The median
age was 62 years (interquartile range 52–72), being significantly higher in dead patients (73)
than in alive patients (59). The majority of participants were male (66.7%) although among
the deceased, there was an equal number of males and females (4). Some comorbidities
were more frequent in poor outcome and dead patients, such as COPD, CRD, immuno-
suppression (these three were statistically significant in death outcome), obesity, neoplasia,
and heart failure. Radiologically, the median chest X-ray severity according to RALE
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was 4 (statistically significant for both main outcomes) and the incidence of pulmonary
thromboembolism 8.6%, more frequent in favourable outcome (10% vs. 5%) and death
(11.1% vs. 8.3%) without reaching statistical significance. In clinical variables, the median
number of symptom days was higher in the living (8 vs. 5) and RR in poor outcome (26
vs. 21, p < 0.01), while in poor outcome and death, altered level of consciousness (5% vs.
3.3% and 22.2% vs. 1.3% with p < 0.01) and supplementary O2 (85% vs. 56.7% with p < 0.05
and 77.8% vs. 62.5%) were more frequent. Analytically, poor outcome and dead patients
presented a higher frequency of levels above the established cut-off points in LDH and
CRP scores although lower in D-dimer and neutrophil-lymphocyte ratio. They also had
lower PaO2-FiO2 ratio and median eGFR (p < 0.01 in death outcome), lymphocyte, and
platelet values (p < 0.05 in both outcomes) while higher NT-proBNP levels (p < 0.05 in
death outcome).
































i re 2. atie t selecti fl c art.
3.2. Main Results
Differences between the subgroups for the two main outcomes under study are
described in Table 1. In total, 21 patients in our cohort had a poor outcome, and nine
patients died. Univariate analysis of each of the scores showed a statistically significant
correlation between poor outcome and NEWS2 (OR 1.611, p < 0.001), LUS > 15 (OR 3.5,
p = 0.019), and COWS (OR 3.968, p = 0.019). The study of death at 28 days showed
statistically significant correlations in NEWS2 (OR 1.315, p = 0.041) and SEIMC Score (OR
1.190, p = 0.008).
Table 1. Differences between favourable and poor outcome and between alive and dead patients.
Vs. Poor Outcome Vs. Dead at 28 Days
p OR (CI) p OR (CI)
NEWS2 0.001 ** 1.611 (1.228–2.113) 0.041 * 1.315 (1.012–1.710)
LUS > 15 0.019 * 3.5 (1.192–10.275) 0.271 2.235 (0.519–9.636)
SEIMC Score 0.516 1.034 (0.935–1.143) 0.008 ** 1.190 (1.046–1.354)
COWS 0.019 * 3.968 (1.251–12.573) 0.243 2.552 (0.530–12.283)
* p < 0.05; ** p < 0.01.
The performance of each of the scores was represented in the pooled ROC curves
(Figure 3), detailing their AUC, optimal cut-point value, sensitivity, and specificity in
Table 2. As in the univariate analysis, NEWS (AUC 0.785), LUS > 15 (0.617), and COWS
(AUC 0.751) showed the best performance at poor outcome. It also coincides in death at
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28 days, with NEWS (AUC 0.654) and SEIMC Score (AUC 0.854) showing the best results
although COWS (AUS 0.690) also performs well. Statistical differences between the AUC of
the scores were also studied according to DeLong’s non-parametric method [21], as shown
in Appendix B. As a result, NEWS (p = 0.028), SEIMC (p = 0.004), and COWS (p < 0.001)
are superior to LUS as a continuous variable for predicting poor outcome, while COWS is
also superior to LUS for predicting death at 28 days (p = 0.007). There is also significant
superiority of NEWS over SEIMC for predicting poor outcome (p = 0.049).





  p  OR (CI)  p  OR (CI) 
NEWS2  0.001 **  1.611 (1.228–2.113)  0.041 *  1.315 (1.012–1.710) 
LUS > 15  0.019 *  3.5 (1.192–10.275)  0.271  2.235 (0.519–9.636) 
SEIMC Score  0.516  1.034 (0.935–1.143)  0.008 **  1.190 (1.046–1.354) 
COWS  0.019 *  3.968 (1.251–12.573)  0.243  2.552 (0.530–12.283) 
* p < 0.05; ** p < 0.01. 















Figure 3. Pooled ROC curves for (a) poor outcome and (b) dead at 28 days.
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Table 2. Performance of prognostic scores for (a) poor outcome and (b) dead at 28 days.
(a)
Poor Outcome AUC Optimal Cut-Off PointValue Sensitivity Specificity
NEWS2 0.785 * >5 0.619 0.850
LUS 0.617 >17 0.619 0.700
SEIMC Score 0.593 >9 0.333 0.783
COWS 0.751 * ≥0.1007 0.857 0.617
(b)
Dead 28 Days AUC Optimal Cut-Off PointValue Sensitivity Specificity
NEWS2 0.654 >5 0.444 0.887
LUS 0.560 >17 0.556 0.634
SEIMC Score 0.840 * >9 0.667 0.803
COWS 0.690 ≥0.1007 0.889 0.431
* AUC > 0.7.
4. Discussion
Most physicians agree on the importance of clinical findings of haemodynamic insta-
bility [22] and analytical findings of hyperinflammation syndrome [23] in the management
of patients with COVID-19, supported by the classical radiological studies of chest x-ray
and chest CT [24]. However, weighing each of these findings separately as a better predictor
of the disease outcome proves to be very complicated. In this context, different scores that
group several of these variables and assign a weight to them have emerged continuously
up to the present time [25–27] as well as alternatives to conventional diagnostic tests, such
as lung ultrasound [28]. However, a new question arises when trying to use these indices in
clinical practice, where effectiveness in the management of time and resources is essential
in a pandemic context. For this reason, we conducted this comparative study between
representative scores of the most commonly used variables in medical practice (clinical,
analytical, and imaging), avoiding some that have raised doubts about their usefulness [29].
Although several studies have attempted to deal with this problem, some of them have
focused on validating previous indices not specific to COVID-19 [30,31], comparing them
with new indices developed particularly for this disease [32,33] or comparing scores that
evaluate one or two categories of the variables used to assess the severity of the disease [34].
However, none of them have validated COVID-specific indices taking into account the
new diagnostic alternative of lung ultrasound or scores derived from it. More and more
clinicians are becoming proficient in this technique, and it is no longer a diagnostic test
offered by the radiology department but an increasingly accessible tool in the emergency
department and on the hospital ward.
The results described above validate many of the original studies that developed
the scores analysed. NEWS2 was confirmed as a useful tool both for predicting severe
disease and for studying in-hospital death, showing significant results for both outcomes
in our cohort. LUS findings had already shown good correlation with disease severity,
repeating these results in this study with a cut-off point of 15. The SEIMC Score data for
30-day mortality were also confirmed, being significantly associated as well with 28-day
death in our study. Finally, the COWS was developed to measure the probability of
developing severe disease and, in our study, not only confirmed this result but also showed
an acceptable diagnostic ability for 28-day mortality according to the AUC (however,
it did not reach the pre-determined statistical significance), with a high sensitivity for
both outcomes.
From the detailed analysis of the results, we appreciate the importance of the cut-off
points. Setting the same cut-off point for the two prognostic variables (death and poor
prognosis) may imply decreasing the utility, predicting one of the variables in favour of
the other. In the case of LUS, on the other hand, it seems that its usefulness as a discrete
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variable is less than as an ordinal variable. Categorising into mild and severe groups with a
cut-off point of 15 (as used by the COWS) has greater statistical significance in our sample
than its AUC. The NEWS is a clinical scale, which measures the impact of COVID-19 at
the time of the evaluation. Perhaps for this reason it is a better predictor of poor outcome,
as clinical variables are established criteria for starting mechanical ventilation. However,
its usefulness in predicting death as an outcome is less in the AUC analysis although
it is possible that with greater sample power it would reach statistical significance, as
it does in simple logistic regression. The COWS has a similar issue, in which a larger
sample size would possibly show statistical significance in the analysis of death as an
outcome (AUC 0.69, having used 0.7 as the cut-off point for statistical significance). Finally,
the SEIMC Score appears to be an index developed specifically to predict death as an
outcome, including the variables that, in the cohort analysed, best predicted this outcome.
Specifically, the inclusion of age and eGFR as variables in their calculation may be two of
the reasons for this. Our study provides external validity to these results but confirms that
it is not a useful score for predicting poor prognosis.
Among the strengths of our study, as an underused clinical tool equal to other more
commonly used techniques such as blood tests, it is worth noting the inclusion of lung
ultrasound and the scores derived from it. Finally, the outcomes measured included both
poor outcome and death at 28 days, in contrast to other studies that assessed only one or
the other, and there were been any missing data among participants.
The study was designed with the purpose to reduce the limitation of being an operator-
dependent technique, with two or more operators always required to be present during
image acquisition and interpretation. However, the biases in lung ultrasound performance
by our team of operators, although mitigated by the presence of other colleagues, were
still present and cannot be completely ruled out. Potential limitations of the study could
arise from the sample size. Although the initial calculation showed us that the sample of
24 patients was sufficient, probably with a larger sample, we could perform a mutivariate
analysis, including joint clinical and ultrasound parameters, and confirm the clear tendency
of some variables to reach statistical significance without reaching it. Participants included
among the eligible patients were recruited on a randomised basis, so we believe that
the patients included are a representative sample of the total population admitted to
the inpatient ward of our hospital and therefore do not represent a bias in itself. In
addition, some parameters, such as D-dimer or cardiovascular disease, are more frequent
in favourable outcomes than in other studies, which could probably change with more
cases favouring regression to the mean. Though a careful selection was made from among
the many existing scores, selecting representative examples of the variables most commonly
used in clinical practice, the continuous proliferation of these indices makes it impossible to
compare all of them. At last, the exclusion of patients with potential bacterial superinfection
in the lung may be a bias that eliminates patients with more severe evolution, while the
inclusion of lung ultrasound implies an operator-dependent technique that may make
reproducibility in other studies difficult.
This study raises some issues that will need to be addressed in further studies. Which
type of transducer (convex or linear) is most suitable for lung ultrasound should be defined
and demonstrated. Most of these scores have also been developed and validated in the
hospitalised population, and studies are needed to test their usefulness in the out-of-
hospital setting. Our study indicates the necessity of establishing LUS cut-off points for
mild, moderate, and severe disease in future studies. We also consider it necessary to
establish guidelines in the elaboration of these scores and to combine those that measure
the same variables into indices with greater statistical power.
5. Conclusions
In summary, NEWS2, LUS, and COWS are good scores for predicting poor outcome of
COVID-19, while NEWS2, SEIMC Score, and COWS are useful scores for predicting death
at 28 days. Both COWS and NEWS are the scores that best predict the evolution of COVID
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patients in our cohort. Lung ultrasound is a diagnostic tool that should be included in the
evaluation of COVID-19 patients.
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Age 62 61 62
0.550
73 59
0.001 **(median, IQR) (52–72) (47.5–72.3) (52.8–71.3) (72–78) (51–70)
Sex
Male (%) 66.7 75 63.9
0.362
55.6 68.1
Female (%) 33.3 25 36.1 44.4 31.9 0.292
Weight [kg] 84 84 84
0.852
83.9 84
0.733(mean, SD) (1.9) (3.3) (2.3) (7.3) (1.9)
Height [cm] 168.7 168 168.9
0.653
165 169
0.868(mean, SD) (1.1) (2.1) (1.3) (3.7) (1.2)
Dementia (%) 2.5 0 3.3 0.412 0 2.7 0.635
COPD 1 (%) 4.9 10 3.3 0.229 33.3 1.4 0.001 **
Chronic renal disease (%) 12.4 15 11.7 0.678 33.3 9.7 0.023 *
Diabetes mellitus (%) 28.4 25 30 0.698 55.6 25 0.153
Hypertension (%) 46.9 30 53.3 0.081 55.6 45.8 0.854
Obesity (%) 34.6 40 33.3 0.600 44.4 33.3 0.505
Neoplasia (%) 15.2 20 13.6 0.414 33.3 12.9 0.064
Hepatitis B virus (%) 0 0 0 - 0 0 -
Cerebrovascular disease (%) 5.1 5 5.1 0.964 0 5.7 0.491



















Cardiovascular disease (%) 8.9 0 11.9 0.119 0 10 0.352
Heart failure (%) 7.6 15 5.1 0.122 22.2 5.7 0.050
Immunosuppression (%) 6.4 10 5.1 0.400 22.2 4.3 0.023 *
Number of comorbidities 1 1 1
0.402
2 1
0.006 **(median, IQR) (0–2) (0–2) (0–2) (2–3) (0–2)
Days of symptoms 8 7 9
0.071
5 8
0.057(median, IQR) (5–10) (4.75–9) (6–10) (4–6) (7–10)
Dyspnea (%) 69.1 75 66.7 0.513 66.7 69.4 0.705
Cough (%) 76.5 75 76.7 0.851 66.7 77.8 0.914
Altered consciousness (%) 3.7 5 3.3 0.724 22.2 1.3 0.001 **
Fever (%) 44.4 50 41.7 0.466 44.4 44.4 0.598
SaO2 2 [%] 96.2 95.2 96.6 0.012 *
95 96.4
0.014 *(mean, SD) (0.2) (0.6) (0.2) (0.9) (0.24)
Supplementary O2 (%) 64.2 85 56.7 0.025 * 77.8 62.5 0.502
RR 3 [breaths/min] 24 26 21
0.009 **
24 24
0.245(median, IQR) (20–28) (24–28) (18–24.5) (22–28) (21–28)
HR 4 [beats/min] 81 85 76
0.030 *
82 81
0.692(median, IQR) (70–90) (79.5–96) (67.8–89) (73–86) (70–90)
SBP 5 (mmHg) 127.3 127.5 127.2
0.939
130.9 126.8
0.893(mean, SD) (1.7) (2.9) (2.1) (7.3) (1.7)
Rx. thorax [RALE 6] 4 4 4
0.019 *
5 4
0.001 **(median, IQR) (3–5) (3–5) (3–5) (5–8) (3–5)
CT PTE 7 (%) 8,6 5 10,0 0.504 11.1 8.3 0.682
PaO2-FiO2 8 ratio 366.3 306.2 388.3 0.001 **
289.9 373.1
0.015 *(mean, SD) (10.8) (23) (11.1) (30.8) (10.8)
Glucose [mg/dL] 147.2 126.75 154
0.139
160.7 145.5
0.862(mean, SD) (7.5) (9.5) (9.4) (22.2) (8)
eGFR 9
0.001 **[ml/min/1.73 m2 9] 80 75 81
0.330
52.6 83.4
(mean, SD) (2.8) (5.9) (3.1) (7.4) (2.7)
AST 10 [U/L] 52.6 66 48.6
0.920
39.2 47.6
0.837(mean, SD) (6.3) (17.7) (6.1) (6.7) (6.5)
Ferritin [ng/mL] 824.6 745.8 848.4 681.5 832.5
(mean, SD) (80.7) (132.7) (99.3) 0.814 (183.3) (87.7) 0.914
>700 ng/mL (%) 44.4 45 43.3 0.852 33.3 45.2 0.731
LDH 11 [U/L] 337.2 365.9 329.6 0.738 339.8 336.9 0.849
(mean, SD) (13.3) (33.4) (14)
0.254
(44.9) (14)
0.769>400 U/L (%) 21 30 18.3 22.2 20.8
CRP 12 [mg/L] 91.5 84.2 92.4
0.473
91.5 91.5
0.681(mean, SD) (6.8) (14.1) (7.7) (23) (7.1)
>15 mg/mL (%) 95.1 100 93.3 0.240 100 94.4 0.497
Lymphocyte [103/µL] 0.87 0.83 0.88
0.763
0.7 0.89
0.101(mean, SD) (0.05) (0.1) (0,06) (0.15) (0.05)
Neutrophil-lymphocyte ratio 6.4 7.3 6.1 0.540 8.6 6.1 0.264
(mean, SD) (0.46) (0.8) (0.6)
0.711
(2.1) (0.4)
0.706>10 (%) 17.3 7.31 16.7 11.1 18.1



















Platelets [103/µL] 200.6 163.4 214
0.008 **
152.6 206.6
0.020 *(mean, SD) (8.3) (12.7) (9.9) (20.6) (8.8)
D dimer [mg/L] 1.68 1.1 1.9 0.144 4.4 1.3 0.168
(mean, SD) (0.5) (0.3) (0.6)
0.538
(3.9) (0.2)







(mean, SD) (171.2) (372.5) (188.7) (731.9) (136.6)
NEWS2 4 6 3
0.001 **
5 3
0.041 *(median, IQR) (2–6) (5–7) (2–5) (3–7) (2–6)
ECO LUS total 15 18 14 0.177 18 15 0.541
(median, IQR) (10–19) (13.5–19) (9.8–18.3)
0.019 *
(10–19) (10–19)
0.271>15 (%) 49.4 70 43.3 66.7 47,2
SEIMC Score 6 6 6
0.516
11 5
0.008 **(median, IQR) (4–10) (5–10) (4–9) (9–14) (4–8)
COWS 0.52 0.72 0.47
0.019 *
0.71 0.5
0.243(mean, SD) (0.05) (0.10) (0.06) (0.15) (0.06)
1 COPD: Chronic obstructive pulmonary disease; 2 SaO2: Peripheral arterial oxygen saturation; 3 RR: Respiration rate; 4 HR: Heart rate;
5 SBP: Systolic blood pressure; 6 RALE: Radiographic Assessment of Lung (O)Edema; 7 CT PTE: Computer Tomography Pulmonary
Thromboembolism; 8 PaO2-FiO2: Arterial oxygen pressure to oxygen inspired fraction ratio; 9 eGFR: Estimated glomerular filtration rate
calculated by the CKD-EPI; 10 AST: Aspartate aminotransferase; 11 LDH: Lactate dehydrogenase; 12 CRP: C-reactive protein; 13 NT-proBNP:
N-terminal pro-brain natriuretic peptide. (* p < 0.05 and ** p < 0.01).
Appendix B






LUS vs. NEWS2 0.028 *(−0.319–0.018)
0.507
(−0.357–0.176)
LUS vs. SEIMC 0.004 **(−0.471–0.090)
0.812
(−0.172–0.220)
LUS vs. COWS < 0.001 **(−0.201–0.067)
0.007 **
(−0.226–0.036)
COWS vs. NEWS2 0.590(−0.160–0.233)
0.676
(−0.151–0.091)
COWS vs. SEIMC 0.059(−0.006–0.322)
0.081
(−0.318–0.018)
NEWS2 vs. SEIMC 0.049 *(0.0003–0.385)
0.126
(−0.435–0.054)
* p < 0.05; ** p < 0.01.
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